Innate and adaptive immunity in the pathogenesis of atherosclerosis

Circulation Research

Volumn 91, Issue 4, 2002, Pages 281-291

  Hansson, Göran K ^a,c   Libby, Peter ^b   Schönbeck, Uwe ^b   Yan, Zhong Qun ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibody; Cytokines; Inflammation; Lymphocytes; Macrophages

Indexed keywords

ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; CELL PROLIFERATION; DISEASE ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODY SPECIFICITY; ARTERIOSCLEROSIS; BLOOD VESSELS; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; LYMPHOCYTES; MACROPHAGES;

EID: 0037163149     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000029784.15893.10     Document Type: Review

References (156)

1. Immune mechanisms in atherosclerosis
2. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions
3. Atherogenesis and inflammation
4. Atherosclerosis: An inflammatory disease
5. Participation of innate and acquired immunity in atherosclerosis
6. Atherosclerosis
7. Immune mechanisms in atherosclerosis
8. Atherosclerosis: The road ahead
9. Innate immunity
10. Innate immune recognition
11. Innate immunity and the normal microflora
12. The other side of scavenger receptors: Pattern recognition for host defense
13. Molecular flypaper, host defense, and atherosclerosis
14. Scavenger receptors in innate immunity
15. The human toll signaling pathway: Divergence of nuclear factor κB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)
16. Bacterial lipopolysaccharide activates NF-κB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: Differential expression of TLR-4 and TLR-2 in endothelial cells
17. LPS induction of gene expression in human monocytes
18. Toll: A new piece in the puzzle of innate immunity
19. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2
20. Mechanisms of antigen uptake for presentation
21. Dendritic cells and the control of immunity
22. Natural antibodies and complement link innate and acquired immunity
23. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity
24. Bacterial lipopolysaccharide and IFN-γ induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: Role of NF-κB activation
25. Expression of Toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation
26. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism
27. Toll-like receptors and innate immunity
28. Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothelium
29. Antigen-presenting function of human endothelial cells: Direct activation of resting CD8 T cells
30. Mechanisms of disease: The L-arginine-nitric oxide pathway
31. Activation of inducible nitric oxide synthase/nitric oxide by curli fibers leads to a fall in blood pressure during systemic Escherichia coli infection in mice
32. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides
33. CD40 signaling and plaque instability
34. The CD40/CD154 receptor/ligand dyad
35. The fate of lipoprotein cholesterol entering the arterial wall
36. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
37. Low density lipoprotein oxidation and its pathobiological significance
38. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis
39. Nonoxidative modifications of lipoproteins in atherogenesis
40. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
41. Recent progress in advanced glycation end products and diabetic complications
42. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
43. Modification of proteins and lipids by myeloperoxidase
44. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders
45. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes
46. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
47. Infection and atherosclerosis: Emerging mechanistic paradigms
48. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL
49. Oxidized phospholipids and isoprostanes in atherosclerosis
50. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins
51. Angiotensin induces inflammatory activation of human vascular smooth muscle cells
52. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
53. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis
54. The combined role of P- and E-selectins in atherosclerosis
55. 1 integrin
56. NF-κB pivotal mediator or innocent bystander in atherogenesis?
57. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice
58. -/- mice reveals a role for chemokines in the initiation of atherosclerosis
59. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells
60. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: Using genomic technology to identify a potential novel pathway of vascular inflammation
61. Atherosclerosis: Scavenging for receptors
62. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis
63. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions
64. The macrophage scavenger receptor type A directs modified proteins to antigen presentation
65. Cell proliferation in human coronary arteries
66. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E
67. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice
68. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice
69. Prelesional complement activation in experimental atherosclerosis
70. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells
71. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation
72. Complement activation and atherosclerosis
73. -/- mice develop atherosclerosis in the absence of complement component C5
74. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque
75. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
76. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1
77. Evidence for a local immune response in atherosclerosis: CD4+ T cells infiltrate lesions of apo E-deficient mice
78. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Thl) and macrophage-stimulating cytokines
79. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis
80. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis
81. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability
82. Hypercholesterolemia is associated with a Th1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice
83. Protective role of interleukin-10 in atherosclerosis
84. Interleukin-10 blocks atherosclerotic events in vitro and in vivo
85. Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholest hypercholesterolaemic apolipoprotein E knockout mice
86. S-100 positive cells in human arterial intima and in atherosclerotic lesions
87. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima: Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta
88. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture
89. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction
90. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-α
91. Mast cell infiltration in acute coronary syndromes: Implications for plaque rupture
92. Role of mast cells in atherosclerosis
93. Structural basis of T cell recognition
94. Oligoclonal T cell expansions in atherosclerotic lesions of apoE-deficient mice
95. Polyclonal origin of T lymphocytes in human atherosclerotic plaques
96. Diversity of T-cell antigen receptor V · gene utilization in advanced human atheroma
97. Restricted usage of T-cell receptor Vα-Vβ genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis
98. Analysis of the T-cell receptor repertoire in human atherosclerosis
99. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia
100. T lymphocytes from human atherosclerotic plaques recognize oxidized LDL
101. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL
102. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum
103. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice
104. Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice
105. Protective immunity carried by B cells of hypercholesterolemic mice
106. Role of hsp60 during autoimmune and bacterial inflammation
107. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65
108. The role of heat shock proteins in protection and pathophysiology of the arterial wall
109. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65
110. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65
111. Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells
112. Immunology of the antiphospholipid syndrome: Antibodies, antigens, and autoimmune response
113. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction
114. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I
115. 2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice
116. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages
117. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration
118. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role
119. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1-β
120. Interferon-γ inhibits both proliferation and expression of differentiation-specific a-smooth muscle actin in arterial smooth muscle cells
121. Cytokines positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells
122. Cellular and vascular manifestations of cell-mediated immunity
123. Osteopontin: A versatile regulator of inflammation and biomineralization
124. Recent advances in multifactorial regulation of vascular calcification
125. Functional CD 40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis
126. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites
127. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques
128. PTX3: A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans
129. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection
130. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice
131. Infectious agents are not necessary for murine atherogenesis
132. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse
133. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice
134. -/- mice
135. IFN-γ potentiates atherosclerosis in apoE knock-out mice
136. -/- mice
137. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
138. Requirement for CD154 in the progression of atherosclerosis
139. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype
140. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice
141. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis
142. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes
143. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits
144. Protection against atherosclerosis by LDL immunization is associated with T cell dependent IgG antibodies in apoE-deficient mice
145. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice
146. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells
147. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: A novel link between vascular inflammation and clotting activation
148. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor
149. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
150. 3 integrin-dependent mechanism
151. Regulation of the fibrinolytic system of cultured human vascular endothelium by IL-1
152. Stability and instability: The two faces of coronary atherosclerosis: The Paul Dudley White Lecture, 1995
153. Coronary plaque disruption
154. The molecular bases of the acute coronary syndromes
155. Evidence for apoptosis in advanced human atheroma: Co-localization with interleukin-1 β-converting enzyme
156. Immune interferon inhibits proliferation and induces 2′-5′-oligoadenylate synthetase gene expression in human vascular smooth muscle cells